title: Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells.
abstract: We previously reported that rOv-ASP-1, a recombinant Onchocerca volvulus activation associated protein-1, was a potent adjuvant for recombinant protein or synthetic peptide-based Ags. In this study, we further evaluated the adjuvanticity of rOv-ASP-1 and explored its mechanism of action. Consistently, recombinant full-length spike protein of SARS-CoV or its receptor-binding domain in the presence of rOv-ASP-1 could effectively induce a mixed but Th1-skewed immune response in immunized mice. It appears that rOv-ASP-1 primarily bound to the APCs among human PBMCs and triggered Th1-biased proinflammatory cytokine production probably via the activation of monocyte-derived dendritic cells and the TLR, TLR2, and TLR4, thus suggesting that rOv-ASP-1 is a novel potent innate adjuvant.
authors.affiliation: Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA. yhe@nybloodcenter.org
authors.forename: Yuxian
authors.initials: Y
authors.lastname: He
authors.forename: Sophie J
authors.initials: SJ
authors.lastname: Barker
authors.forename: Angus J
authors.initials: AJ
authors.lastname: MacDonald
authors.forename: Yu
authors.initials: Y
authors.lastname: Yu
authors.forename: Long
authors.initials: L
authors.lastname: Cao
authors.forename: Jingjing
authors.initials: J
authors.lastname: Li
authors.forename: Ranjit
authors.initials: R
authors.lastname: Parhar
authors.forename: Susanne
authors.initials: S
authors.lastname: Heck
authors.forename: Susanne
authors.initials: S
authors.lastname: Hartmann
authors.forename: Douglas T
authors.initials: DT
authors.lastname: Golenbock
authors.forename: Shibo
authors.initials: S
authors.lastname: Jiang
authors.forename: Nathan A
authors.initials: NA
authors.lastname: Libri
authors.forename: Amanda E
authors.initials: AE
authors.lastname: Semper
authors.forename: William M
authors.initials: WM
authors.lastname: Rosenberg
authors.forename: Sara
authors.initials: S
authors.lastname: Lustigman
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D000938:Antigen-Presenting Cells / Q000276:immunology*; D000947:Antigens, Helminth / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D015801:Helminth Proteins / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000276:immunology; D051379:Mice; D011994:Recombinant Proteins / Q000276:immunology*; D064370:Spike Glycoprotein, Coronavirus; D018417:Th1 Cells / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000276:immunology; D051197:Toll-Like Receptor 4 / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000947:Antigens, Helminth; D016207:Cytokines; D015801:Helminth Proteins; D008562:Membrane Glycoproteins; C414408:Ov-ASP-1 protein, Onchocerca volvulus; D011994:Recombinant Proteins; D064370:Spike Glycoprotein, Coronavirus; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D014759:Viral Envelope Proteins